PHILIP LOTTINGER: Open Payments
NPI 1013635937 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,224 in 57 payments from 14 companies in 2025. Trend: 2023 $707 · 2024 $984 · 2025 $1,224
Food & beverage: $1,224
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $239 |
| Janssen Pharmaceuticals, Inc | 6 | $233 |
| Neurocrine BioSciences, Inc. | 8 | $168 |
| E.R. Squibb & Sons, L.L.C. | 9 | $139 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $113 |
| Alkermes, Inc. | 4 | $76 |
| Corium, LLC | 5 | $61 |
| Merck Sharp & Dohme LLC | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
Products named: VRAYLAR, SPRAVATO, INGREZZA, COBENFY, CAPLYTA, ARISTADA, Azstarys, PIFELTRO.
Industry payments across LA — which companies pay providers there.
